Renaissance Technologies LLC raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 249.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 63,618 shares of the life sciences company’s stock after purchasing an additional 45,400 shares during the period. Renaissance Technologies LLC’s holdings in Illumina were worth $17,768,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Kaizen Advisory LLC boosted its stake in shares of Illumina by 161.0% in the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after acquiring an additional 227 shares during the period. Sun Life Financial INC boosted its stake in shares of Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after acquiring an additional 241 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Illumina by 3,192.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after acquiring an additional 415 shares during the period. Hall Laurie J Trustee boosted its stake in shares of Illumina by 189.5% in the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock worth $154,000 after acquiring an additional 360 shares during the period. Finally, Segall Bryant & Hamill LLC bought a new position in shares of Illumina in the second quarter worth about $201,000. 89.80% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ILMN opened at $361.45 on Thursday. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $52.66 billion, a P/E ratio of 90.36, a PEG ratio of 2.97 and a beta of 0.97. Illumina, Inc. has a 12 month low of $196.00 and a 12 month high of $365.86.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.32. The company had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The firm’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 earnings per share. equities research analysts anticipate that Illumina, Inc. will post 5.46 EPS for the current year.

A number of equities analysts have recently weighed in on ILMN shares. Morgan Stanley upped their price objective on Illumina from $180.00 to $195.00 and gave the stock an “underweight” rating in a research note on Thursday, May 31st. Citigroup upped their price objective on Illumina from $275.00 to $330.00 and gave the stock a “buy” rating in a research note on Monday, June 25th. Cowen upped their price objective on Illumina from $275.00 to $315.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. Piper Jaffray Companies upped their price objective on Illumina from $272.00 to $329.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $340.00 price objective (up previously from $330.00) on shares of Illumina in a research note on Friday, July 27th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $320.69.

In related news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $351.66, for a total value of $1,160,478.00. Following the sale, the director now directly owns 392,204 shares in the company, valued at $137,922,458.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert S. Epstein sold 1,346 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $345.14, for a total value of $464,558.44. Following the completion of the sale, the director now owns 7,139 shares in the company, valued at $2,463,954.46. The disclosure for this sale can be found here. Insiders sold 45,337 shares of company stock worth $14,795,288 over the last quarter. 0.54% of the stock is owned by company insiders.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Outstanding Shares

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.